NO20044815L - Behandling av gastroparese - Google Patents

Behandling av gastroparese

Info

Publication number
NO20044815L
NO20044815L NO20044815A NO20044815A NO20044815L NO 20044815 L NO20044815 L NO 20044815L NO 20044815 A NO20044815 A NO 20044815A NO 20044815 A NO20044815 A NO 20044815A NO 20044815 L NO20044815 L NO 20044815L
Authority
NO
Norway
Prior art keywords
gastroparesis
treatment
glp
patients
compounds
Prior art date
Application number
NO20044815A
Other languages
English (en)
Inventor
Joseph Anthony Jakubowski
Thurman Dwight Mckinney
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20044815L publication Critical patent/NO20044815L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Oppfinnelsen angår anvendelse av GLP- 1 -forbindelser for behandling av gastroparese. Pasienter med gastroparese opplever vanligvis en forsinkelse i gastrisk tømming. GLP- I -forbindelser kan anvendes for å regulere gastfisk tømming hos disse pasienter.
NO20044815A 2002-04-10 2004-11-05 Behandling av gastroparese NO20044815L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37165002P 2002-04-10 2002-04-10
PCT/US2003/008457 WO2003087139A2 (en) 2002-04-10 2003-03-27 Treatment of gastroparesis

Publications (1)

Publication Number Publication Date
NO20044815L true NO20044815L (no) 2005-01-07

Family

ID=29250714

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044815A NO20044815L (no) 2002-04-10 2004-11-05 Behandling av gastroparese

Country Status (18)

Country Link
US (1) US20050164925A1 (no)
EP (1) EP1496924A4 (no)
JP (1) JP2005530732A (no)
KR (1) KR20040098063A (no)
CN (1) CN1735423A (no)
AU (1) AU2003220403A1 (no)
BR (1) BR0308904A (no)
CA (1) CA2480858A1 (no)
EA (1) EA200401345A1 (no)
EC (1) ECSP045345A (no)
HR (1) HRP20040939A2 (no)
IL (1) IL164266A0 (no)
MX (1) MXPA04009929A (no)
NO (1) NO20044815L (no)
NZ (1) NZ535684A (no)
PL (1) PL373658A1 (no)
WO (1) WO2003087139A2 (no)
ZA (1) ZA200408111B (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8666495B2 (en) 1999-03-05 2014-03-04 Metacure Limited Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar
US9101765B2 (en) 1999-03-05 2015-08-11 Metacure Limited Non-immediate effects of therapy
US8792985B2 (en) 2003-07-21 2014-07-29 Metacure Limited Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar
EP1667724A2 (en) * 2003-09-19 2006-06-14 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
CA2539253A1 (en) * 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
EP1793891B1 (en) 2004-08-18 2011-11-09 Metacure Limited Monitoring, analysis, and regulation of eating habits
WO2006087712A2 (en) 2005-02-17 2006-08-24 Metacure N.V. Charger with data transfer capabilities
US9821158B2 (en) 2005-02-17 2017-11-21 Metacure Limited Non-immediate effects of therapy
KR20070120112A (ko) 2005-03-18 2007-12-21 노보 노르디스크 에이/에스 연장형 ｇｌｐ-1 화합물
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US8463404B2 (en) 2005-03-24 2013-06-11 Metacure Limited Electrode assemblies, tools, and methods for gastric wall implantation
ATE533403T1 (de) * 2005-03-24 2011-12-15 Metacure Ltd Drahtlose leitungen für magen-darm-trakt- anwendungen
WO2006129321A2 (en) 2005-06-02 2006-12-07 Metacure N.V. Gi lead implantation
US8442841B2 (en) * 2005-10-20 2013-05-14 Matacure N.V. Patient selection method for assisting weight loss
US8295932B2 (en) 2005-12-05 2012-10-23 Metacure Limited Ingestible capsule for appetite regulation
AU2012203915B9 (en) * 2006-04-20 2014-10-09 Amgen Inc. GLP-1 compounds
CA2648936C (en) * 2006-04-20 2013-07-09 Amgen Inc. Glp-1 compounds
EP2150308B1 (en) * 2007-05-09 2018-08-08 MetaCure Limited Analysis and regulation of food intake
US8423130B2 (en) * 2008-05-09 2013-04-16 Metacure Limited Optimization of thresholds for eating detection
KR20110039348A (ko) 2008-08-06 2011-04-15 노보 노르디스크 헬스 케어 악티엔게젤샤프트 연장된 생체내 효능을 가지는 콘쥬게이트된 단백질
KR20110122100A (ko) 2009-01-22 2011-11-09 노보 노르디스크 헬스 케어 악티엔게젤샤프트 안정한 성장 호르몬 화합물
EP2461831B1 (en) 2009-08-06 2018-11-21 Novo Nordisk Health Care AG Growth hormones with prolonged in-vivo efficacy
US8642548B2 (en) * 2009-08-07 2014-02-04 Mannkind Corporation Val (8) GLP-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome
CN102834109B (zh) 2010-01-22 2016-01-20 诺沃—诺迪斯克保健股份有限公司 稳定的生长激素化合物
JP5980689B2 (ja) 2010-01-22 2016-08-31 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
US8934975B2 (en) 2010-02-01 2015-01-13 Metacure Limited Gastrointestinal electrical therapy
KR20130093470A (ko) 2010-04-30 2013-08-22 가부시키가이샤산와카가쿠켄큐쇼 생리활성 물질 등의 생체 내 안정성 향상을 위한 펩티드 및 생체 내 안정성이 향상된 생리활성 물질
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
AU2013366691A1 (en) 2012-12-21 2015-07-09 Sanofi Exendin-4 derivatives
JP6464145B2 (ja) 2013-04-05 2019-02-06 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 成長ホルモン化合物製剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268343B1 (en) * 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
CA2283834A1 (en) * 1997-03-31 1998-10-08 James Arthur Hoffmann Glucagon-like peptide-1 analogs
IL142707A0 (en) * 2000-04-27 2002-03-10 Pfizer Prod Inc Methods of treating obesity using a neurotensin receptor ligand

Also Published As

Publication number Publication date
JP2005530732A (ja) 2005-10-13
EP1496924A2 (en) 2005-01-19
IL164266A0 (en) 2005-12-18
EP1496924A4 (en) 2007-05-30
KR20040098063A (ko) 2004-11-18
HRP20040939A2 (en) 2004-12-31
CA2480858A1 (en) 2003-10-23
EA200401345A1 (ru) 2005-08-25
BR0308904A (pt) 2005-05-03
CN1735423A (zh) 2006-02-15
US20050164925A1 (en) 2005-07-28
WO2003087139A3 (en) 2004-01-08
WO2003087139A2 (en) 2003-10-23
PL373658A1 (en) 2005-09-05
ECSP045345A (es) 2006-04-19
AU2003220403A1 (en) 2003-10-27
ZA200408111B (en) 2005-10-07
MXPA04009929A (es) 2006-03-10
NZ535684A (en) 2006-03-31

Similar Documents

Publication Publication Date Title
NO20044815L (no) Behandling av gastroparese
IS7738A (is) Þíasól efnasambönd til notkunar í meðferð á taugahrörnunar truflunum.
NO20052796L (no) Indolylpyrazinonderivater anvendelige for behandling av hyper-proliferative forstyrrelser og sykdommer assosiert med angiogenese
GEP20084499B (en) USE OF INTERFERON-ß FOR TREATMENT OF RENAL FAILURE
UA85597C2 (ru) Четвертичные соли как антагонисты ccr2
IS8142A (is) Læknislyf gagnleg til meðferðar á verkjum
NO20084341L (no) Anvendelse av DPP-IV inhibitorer
NO20054371L (no) Somatostatin-dopamin kimaere analoger
NZ609280A (en) Method for treatment of constipation-predominant irritable bowel syndrome
NO20071534L (no) Behandling av inflammatoriske forstyrrelser og smerte
PL1648513T3 (pl) Zastosowanie przeciwciał z optymalizowaną adcc do leczenia pacjentów słabo odpowiadających na leczenie przeciwciałami
EP1789034A4 (en) COMPOUNDS HAVING A DIPHENYL STRUCTURE FOR THE TREATMENT OF IMMUNE DISEASES
ATE384058T1 (de) Thiazolderivate
NO20071378L (no) Tiazolo-naftylsyrer.
IL178827A0 (en) Use of reboxetine for the treatment of pain
PL377164A1 (pl) Pochodne anilinopirazolu przydatne do leczenia cukrzycy
TW200631584A (en) A medicament related to mirtazapine for the treatment of hot flush
MXPA05001885A (es) El uso de una combinacion de ciclesonida y antihistaminas para el tratamiento de la rinitis alergica.
HK1061817A1 (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
MXPA05011699A (es) Inhibidores de la bomba de protones para el tratamiento de trastornos del abdomen inferior.
DK1530462T3 (da) 1-phenyl-2-dimethylaminomethylcyclohexanforbindelser til behandling af depressionssymtomer. smerte og inkontinens
NO20074913L (no) Enhetsdoseringsformer av temozolomid
GEP20094699B (en) THERAPIES FOR CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY USING ß-INTERFERON
GB0415181D0 (en) Compounds for use in the treatment of infection
AU2003255843A1 (en) 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain